Literature DB >> 21794939

C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes.

Lavinia Forte1, Giovanni Cimmino, Francesco Loffredo, Raffaele De Palma, Gianfranco Abbate, Paolo Calabrò, Diego Ingrosso, Patrizia Galletti, Ciro Carangio, Beniamino Casillo, Raffaele Calabrò, Paolo Golino.   

Abstract

BACKGROUND: C-reactive protein (CRP) plasma levels correlate with cardiovascular events. Although a direct role for CRP in atherothrombosis has been suggested, at the moment little is known about its involvement in the pathophysiology of acute coronary syndromes (ACS). Thus, the aim of this study was to determine whether CRP is produced in the culprit lesion and released within the coronary circulation of patients with ACS and whether it may affect coronary endothelial function.
METHODS: Blood samples were simultaneously obtained from the aorta (Ao) and the coronary sinus (CS) of patients with normal coronary artery (n=16), stable angina (n=30), and ACS (n=29) for later measurement of plasma CRP levels. Endothelium-dependent and -independent coronary vasodilation were evaluated by means of a Doppler Flow Wire in response to the increasing intracoronary doses of acetylcholine and adenosine, respectively.
RESULTS: CRP plasma levels were significantly higher across the coronary circulation only in ACS patients with the culprit lesion located in the left coronary artery, while no differences between CS and Ao CRP plasma levels were observed in all other groups. Transcardiac CRP levels were correlated with impairment in coronary endothelium-dependent vasodilation. In six additional patients (SA=3 and ACS=3), subjected to coronary atherectomy, real-time quantitative PCR revealed presence of CRP mRNA only in unstable plaques.
CONCLUSIONS: Thus, CRP is produced and released within the coronary circulation of patients with ACS; this is associated with impairment of endothelial function, suggesting a new pathophysiological link between CRP and ACS.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21794939     DOI: 10.1016/j.ijcard.2011.05.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  Increased local cytokine production at culprit superficial femoral artery plaques.

Authors:  Cameron W Donaldson; David J Schneider; Daniel J Bertges; Julie E Adams; Nader Z Elgharib; Enkhtuyaa L Mueller; William Prabhu; Taka Ashikaga; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

Review 2.  The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.

Authors:  Felice Gragnano; Simona Sperlongano; Enrica Golia; Francesco Natale; Renatomaria Bianchi; Mario Crisci; Fabio Fimiani; Ivana Pariggiano; Vincenzo Diana; Andreina Carbone; Arturo Cesaro; Claudia Concilio; Giuseppe Limongelli; Mariagiovanna Russo; Paolo Calabrò
Journal:  Mediators Inflamm       Date:  2017-05-28       Impact factor: 4.711

Review 3.  Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis.

Authors:  Feifei Li; Xia Guo; Shi-You Chen
Journal:  Front Cardiovasc Med       Date:  2017-05-22

4.  The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia.

Authors:  Vahit Demir; Mehmet Tolga Doğru; Hüseyin Ede; Samet Yilmaz; Cağlar Alp; Yunus Celik; Nesligül Yildirim
Journal:  Cardiovasc J Afr       Date:  2018-03-08       Impact factor: 1.167

5.  Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile.

Authors:  Magdalena Krintus; Marek Kozinski; Anna Stefanska; Marcin Sawicki; Karolina Obonska; Tomasz Fabiszak; Jacek Kubica; Grazyna Sypniewska
Journal:  Mediators Inflamm       Date:  2012-10-16       Impact factor: 4.711

6.  Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.

Authors:  Xuan Zhao; Jian-qing Du; Dan-yan Xu; Shui-ping Zhao
Journal:  Lipids Health Dis       Date:  2013-01-10       Impact factor: 3.876

7.  High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.

Authors:  Giovanni Cimmino; Giovanni Ciccarelli; Alberto Morello; Michele Ciccarelli; Paolo Golino
Journal:  Transl Med UniSa       Date:  2014-09-01

8.  Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis.

Authors:  Sylvain Mathieu; Marion Couderc; Baptiste Glace; Bruno Pereira; Anne Tournadre; Jean-Jacques Dubost; Martin Soubrier
Journal:  Biologics       Date:  2013-12-02

9.  Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque.

Authors:  Giovanni Cimmino; Francesco S Loffredo; Alberto Morello; Saverio D'Elia; Raffaele De Palma; Plinio Cirillo; Paolo Golino
Journal:  Curr Cardiol Rev       Date:  2017

10.  Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism.

Authors:  Rai Ajit K Srivastava; Joseph A Cornicelli; Bruce Markham; Charles L Bisgaier
Journal:  Mol Cell Biochem       Date:  2018-04-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.